Targeting IL-17 in inflammatory disease
The interleukin-17 (IL-17) family cytokines are strong inducers of inflammation and help to protect us against invading pathogens. However, they also have a dark side and contribute to the tissue destruction that occurs in chronic inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis and multiple sclerosis.
The landmark discovery that IL-17-producing T cells were central drivers of these diseases positioned IL-17 as a promising therapeutic target. Several approaches that disrupt signalling by this cytokine family are now being tested in the clinic. Excitingly, real benefits for patients are starting to emerge, particularly for patients with psoriasis.
This collection of Research and Review-type articles highlights the role of the IL-17 pathway in inflammatory diseases, and how our improved understanding of the mechanisms of disease has revealed new opportunities for and potential benefits of IL-17-targeted therapies.
The content for this collection has been chosen by the editors of Nature Reviews Immunology and selected Comment and Review articles have been made freely available for 6 months, thanks to support from Eli Lilly and Company.
In addition, Nature Reviews Drug Discovery presents a Poster that summarizes the key aspects of the IL-17 pathway relevant to its potential as a therapeutic target, and an Animation of the immunopathology of psoriasis that illustrates how agents that target IL-17 signalling are being developed into novel therapies for this disease and other inflammatory conditions.
Poster
Targeting the IL-17 pathway in inflammatory disease
Pierre Miossec
The discovery of T helper 17 cells and interleukin-17 (IL-17) — a pro-inflammatory cytokine that plays a key part in inflammation, autoimmunity and host defence — are recent milestones in the field of immunology and inflammation research. Multiple drugs that target the IL-17 pathway are being investigated in clinical trials for various inflammatory diseases, and the first therapeutic antibody that inhibits IL-17 was approved for the treatment of psoriasis in 2015. This poster summarizes key aspects of the IL-17 pathway relevant to its potential as a therapeutic target, and highlights the current status of the drug development pipeline.
View this poster as a high-resolution PDF (654 kB)
Animation
Psoriasis and beyond: targeting the IL-17 pathway
Psoriasis is a chronic immune-mediated inflammatory skin disorder that affects about 2-3% of the population. New insights into the immune processes that underlie psoriasis have now led to the identification of a number of exciting drug targets. This animation explores the immunopathology of psoriasis and illustrates how agents that target the cytokine interleukin 17, or its upstream or downstream mediators, are being developed into novel therapies for psoriasis.
